Article Information
- Received May 27, 2011
- Revision received July 11, 2011
- Accepted July 21, 2011
- First published September 14, 2011.
- Version of record published September 14, 2011.
Author Information
- 1Department of Psychology, Harvard University, Cambridge, Massachusetts 02138,
- 2Center for Human Genetic Research, Massachusetts General Hospital, and
- 3Bipolar Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, and
- 4Center For Depression, Anxiety and Stress Research and Neuroimaging Center, McLean Hospital and Harvard Medical School, Belmont, Massachusetts 02478
Author contributions
Author contributions: R.B. and D.A.P. designed research; R.B. performed research; R.B., D.L.S., J.F., R.H.P., and D.A.P. contributed unpublished reagents/analytic tools; R.B., D.L.S., J.F., R.H.P., and D.A.P. analyzed data; R.B., D.L.S., J.F., R.H.P., and D.A.P. wrote the paper.
Disclosures
- Received May 27, 2011.
- Revision received July 11, 2011.
- Accepted July 21, 2011.
This work was supported by Sackler Scholar in Psychobiology (Harvard University) and Mind, Brain, and Behavior (Harvard University) grants awarded to R.B., and by NIMH Grants R01 MH68376 and R21 MH078979, Merck Awards for Genome-Related Research (Harvard University), Talley Fund (Harvard University) grants, and a 2008 National Alliance for Research on Schizophrenia and Depression Independent Investigator Award (D.A.P.). We thank Brian Galloway, Miles Nugent, Avram Holmes, Yuliya Nikolova, Sara Rubenstein, Courtney Bagge, Scott Coffey, and Yan Emily Yuan for their assistance. Parts of this paper have been presented previously at the 22nd Annual Meeting of the Society for Research in Psychopathology (September 2008; Pittsburgh, PA), the 23rd Annual Meeting of the Society for Research in Psychopathology (September 2009; Minneapolis, MN), and the 49th Annual Meeting of the Society for Psychophysiological Research (October 2009; Berlin, Germany).
D.A.P. has received consulting fees from ANT North America Inc. (Advanced Neuro Technology) and AstraZeneca, and honoraria from AstraZeneca. R.H.P. has received honoraria and speaker's or consulting fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Pfizer, and Proteus. R.H.P. is a major stockholder in Concordant Rater Systems, LLC. R.B., D.L.S., and J.F. declare no competing financial interests.
- Correspondence should be addressed to Diego A. Pizzagalli, Center for Depression, Anxiety and Stress Research, McLean Hospital, 115 Mill Street, Belmont, MA 02478. dap{at}mclean.harvard.edu
Online Impact